8-K: FOXO Technologies Forms New Acquisition Subsidiary, Appoints Interim CFO Amidst Unexpected Passing

FOXO Technologies Inc. announced the formation of a new wholly-owned subsidiary for healthcare acquisitions, plans for a new preferred stock to fund these acquisitions, and the appointment of Seamus Lagan as Interim CFO following the unexpected passing of Martin Ward.

Summary

• FOXO Technologies Inc. has formed FOXO Acquisition Corporation, a new wholly-owned subsidiary, to acquire targets in the healthcare services and related sectors.
• The company intends to create a new series of publicly listed, non-convertible preferred stock with its own trading symbol to fund these acquisitions, aiming for a non-dilutive financing mechanism for common stockholders.
• The preferred stock is anticipated to generate both cash and common stock dividends for investors and will have a secured interest in the acquisition vehicle.
• Martin Ward, the company's Interim Chief Financial Officer, unexpectedly passed away on June 9, 2025.
• Seamus Lagan, who also serves as the company's CEO and a director, was appointed Interim Chief Financial Officer on June 13, 2025, while a search for a permanent CFO is underway.
• The company amended its Exchange Agreement with Smithline Family Trust II, increasing the Rights Shares from 1,308,751 to 5,151,721 post-split shares of Class A Common Stock, with 1,308,751 shares already issued.
• Approximately $384,297 remains outstanding to Smithline from a November 7, 2023, settlement agreement, which would require approximately 1,800,000 shares to settle based on the June 13, 2025, closing share price.

Sentiment

Score: 4

Explanation: The sentiment is mixed but leans negative due to the unexpected passing of the Interim CFO and the significant increase in shares for the Smithline settlement, which implies greater dilution. While the strategic move to form an acquisition vehicle and plan for non-dilutive preferred stock funding is positive, the immediate negative events and potential dilution overshadow the forward-looking strategic positives in the short term.

Positives

• Formation of FOXO Acquisition Corporation signals a clear strategic direction towards growth through acquisitions in the healthcare sector.
• The plan to use a new series of non-convertible preferred stock for acquisitions aims to be non-dilutive to common stockholders.
• The preferred stock is designed to offer attractive features to investors, including cash and common stock dividends and a secured interest in acquired businesses.
• The company is actively pursuing a strategy to create long-term value for common stockholders by targeting acquisitions with significant growth opportunities and/or surplus cash flow.

Negatives

• The unexpected passing of Martin Ward, the Interim Chief Financial Officer, creates an immediate leadership void and requires a search for a new permanent CFO.
• The amendment to the Exchange Agreement with Smithline Family Trust II significantly increased the number of post-split shares to be issued from 1,308,751 to 5,151,721, which could imply increased dilution for existing common stockholders.
• A remaining liability of approximately $384,297 to Smithline, which would require an additional 1,800,000 shares to settle, indicates ongoing financial obligations that could further impact share count.

Risks

• The company operates in competitive and highly regulated industries, which could impact its performance.
• Variations in operating performance across competitors or changes in laws and regulations could adversely affect FOXO's business.
• There is a risk regarding the company's ability to successfully implement its business plans, forecasts, and other expectations.
• The ability to obtain necessary financing for its strategic initiatives, including acquisitions, is not guaranteed.
• FOXO has a history of losses and may not achieve or maintain profitability in the future.
• There is a potential inability for FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans.
• Risks related to the enforceability of FOXO's intellectual property, including its patents, and the potential infringement on the intellectual property rights of others.
• The company is exposed to the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates.

Future Outlook

FOXO Technologies plans to actively pursue acquisitions in the healthcare services and related sectors through its newly formed subsidiary, FOXO Acquisition Corporation. The company intends to fund these acquisitions by creating and publicly listing a new series of non-convertible preferred stock, which is anticipated to generate cash and common stock dividends for investors and provide a secured interest in the acquired businesses. This strategy aims to achieve significant growth and create long-term value for common stockholders in a non-dilutive manner.

Management Comments

• "We are excited to be taking one of the first tangible steps of our planned acquisition strategy."
• "We believe we can secure the funding we need in a manner that is non-dilutive to our common stockholders and target acquisitions with significant growth opportunities and/or surplus cash flow that will create long-term value for our common stockholders."
• "It is with deep regret and profound sadness that I announce Martins recent passing. Martin was a valuable contributor to our team and he will be sorely missed. My deepest condolences go out to the Ward family."

Industry Context

FOXO Technologies operates within the healthcare services and biotechnology sectors, with existing subsidiaries in critical access hospital operations, behavioral health, and biotechnology research. The formation of FOXO Acquisition Corporation and the strategy to acquire additional healthcare service entities indicate a strategic expansion within the healthcare delivery and related industries. This move aligns with broader trends of consolidation and diversification within the healthcare sector, as companies seek to expand their service offerings and market reach. The planned use of preferred stock for acquisitions is a financing strategy that could be seen in various industries for growth, aiming to minimize common stock dilution.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased dilution due to the significant increase in shares for the Smithline settlement and the additional shares needed for the remaining liability. However, the new acquisition strategy, if successful and non-dilutive as planned, could create long-term value.
• Employees: The unexpected passing of the Interim CFO may cause some disruption and uncertainty, though an interim replacement has been appointed.
• Potential Investors (Preferred Stock): The company is creating a new investment opportunity with anticipated dividends and secured interest, potentially attracting new capital.

Next Steps

• Initiate a search for a new permanent Chief Financial Officer.
• Proceed with the acquisition strategy, including identifying and acquiring targets in the healthcare services and related sectors.
• Create and publicly list the new series of non-convertible preferred stock to fund acquisitions.

Key Dates

Keywords

FOXO Technologies, SEC Filing, 8-K, Healthcare Acquisitions, Preferred Stock, Interim CFO, Management Change, Corporate Strategy, Financial Settlement, Smithline Family Trust II, Rennova Community Health, Myrtle Recovery Centers, FOXO Labs, Biotechnology, Hospital, Behavioral Health